Jury Finds for Takeda in Diabetes Drug Case

Takeda Pharmaceutical Company Ltd and its wholly-owned subsidiary, Takeda Pharmaceuticals USA, Inc. have announced that in the case of the Whitlatch v. Takeda the jury found in favor of Takeda. The trial began on 21 April in the Circuit Court of Cook County, Illinois, before Judge Deborah Dooling and is the fifth ACTOS (pioglitazone HCl) case to reach trial.

“We empathize with the Whitlatch family but agree with the verdict,” said Kenneth D. Greisman, senior vice president, general counsel, Takeda Pharmaceuticals USA, Inc. “Takeda is confident in the therapeutic benefits of ACTOS and its importance as a treatment for type 2 diabetes.”

Takeda prevailed in three previous ACTOS trials and is challenging the outcome of the fourth.

“Patient safety is a critical priority for Takeda,” said Greisman. “We believe that we have acted responsibly with regard to ACTOS and plan to vigorously defend the company against future lawsuits of this type.”

Indication for ACTOS

ACTOS (pioglitazone) is a prescription medicine used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS is not for the treatment of type 1 “juvenile” diabetes or diabetic ketoacidosis (increased ketones in blood or urine).